Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Dermatologic 2

Conditions

Melanoma 2Carcinoma, Renal Cell 2Urologic Neoplasms 1Skin Neoplasms 1Neoplasms 1Kidney Neoplasms 1

Interventions

Sunitinib 145Nivolumab 144pembrolizumab 132Sorafenib 84Bevacizumab 77Everolimus 74cabozantinib 71pazopanib 65Axitinib 65Ipilimumab 62aldesleukin 52Magnetic Resonance Spectroscopy 45Cyclophosphamide 40Interleukin-2 38lenvatinib 37Specimen Handling 36Radiosurgery 36Interferon-alpha 32atezolizumab 30temsirolimus 27belzutifan 24Gemcitabine 23fludarabine phosphate 22avelumab 22Radiotherapy 19Interferon alpha-2 19Biopsy 18fludarabine 17durvalumab 17Nephrectomy 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × flt3 ligand protein × Genitourinary × Clear all
NCT00019396 2024-03-04

flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer

National Cancer Institute (NCI)

Phase 2 Completed
DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma, Neoplasms, Skin Neoplasms, Urologic Neoplasms

NCT00020540 2015-04-30

Biological Therapy in Treating Patients With Metastatic Melanoma or Metastatic Kidney Cancer

National Cancer Institute (NCI)

Phase 1 Completed
DermatologicGenitourinary

Carcinoma, Renal Cell, Kidney Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡